Earnings summaries and quarterly performance for Tarsus Pharmaceuticals.
Executive leadership at Tarsus Pharmaceuticals.
Bobak Azamian
Detailed
Chief Executive Officer
CEO
AM
Aziz Mottiwala
Detailed
Chief Commercial Officer
BW
Bryan Wahl
Detailed
General Counsel and Secretary
DW
Dianne Whitfield
Detailed
Chief Human Resources Officer
EY
Elizabeth Yeu-Lin
Detailed
Chief Medical Officer
JF
Jeffrey Farrow
Detailed
Chief Financial Officer and Chief Strategy Officer
SN
Seshadri Neervannan
Detailed
Chief Operating Officer
Board of directors at Tarsus Pharmaceuticals.
Research analysts who have asked questions during Tarsus Pharmaceuticals earnings calls.
Cory Jubinville
LifeSci Capital
4 questions for TARS
Also covers: CRNX, LQDA
EH
Eddie Hickman
Guggenheim Securities
4 questions for TARS
Also covers: AXSM, OTLK, ZVRA
LH
Lachlan Hanbury-Brown
William Blair & Company
4 questions for TARS
Also covers: APLS, ARSP, EYEN +4 more
AN
Andrea Newkirk
Goldman Sachs
3 questions for TARS
Also covers: ABCL, ALKS, ARWR +9 more
Jason Gerberry
Bank of America Merrill Lynch
3 questions for TARS
Also covers: ALKS, AMPH, ARWR +21 more
FB
François Brisebois
Oppenheimer & Co. Inc.
2 questions for TARS
Also covers: ACHV, AQST, AVDL +11 more
OL
Oren Livnat
H.C. Wainwright
2 questions for TARS
Also covers: ANIP, AVDL, CARA +7 more
Andreas Argyrides
Oppenheimer & Co. Inc.
1 question for TARS
Also covers: AQST, ARSP, CLSD +7 more
AT
Andrea Tan
Goldman Sachs
1 question for TARS
Also covers: ABCL, ARWR, DAWN +3 more
BP
Balaji Prasad
Barclays
1 question for TARS
Also covers: ALVO, AMRX, ELAN +7 more
MC
Matthew Caufield
H.C. Wainwright & Co., LLC
1 question for TARS
Also covers: DMAC, MLYS, OPTN +1 more
PP
Pavan Patel
Bank of America
1 question for TARS
Also covers: AMPH, CPRX, HRMY
Recent press releases and 8-K filings for TARS.
Tarsus Pharmaceuticals Reports Strong Q3 Performance and Updates on Pipeline and Guidance
TARS
Earnings
Guidance Update
New Projects/Investments
- Tarsus Pharmaceuticals reported strong Q3 2025 revenue of almost $119 million for XDEMVY and provided Q4 2025 revenue guidance of $140-$145 million, projecting full-year 2025 revenues between $440-$445 million.
- The company adjusted its long-term gross-to-net discount expectation to 43%-45% due to a higher mix of Medicare patients.
- Tarsus is progressing its pipeline, with a Phase 2 study for ocular rosacea (TP-04) commencing by year-end 2025 and top-line data anticipated in H2 2026.
- The company is well-capitalized, holding approximately $400 million at the end of Q3 2025 to support its commercial product and pipeline development.
Nov 11, 2025, 7:30 PM
Tarsus Reports Strong Q3 2025 XDEMVY Sales and Provides Full-Year Guidance
TARS
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Tarsus reported XDEMVY net sales of $118.7 million for Q3 2025, marking approximately 147% year-over-year growth.
- The company delivered over 103,000 XDEMVY bottles to patients in Q3 2025.
- For Q4 2025, Tarsus anticipates XDEMVY net product sales to be between $140 million and $145 million, with full-year 2025 XDEMVY net product sales projected to range from $440 million to $445 million.
- Tarsus plans to initiate a Phase 2 study for TP-04 (ocular rosacea) in Q4 2025 and a Phase 2 study for TP-05 (Lyme disease prevention) in 2026, while also progressing towards a potential submission in Europe in 2026 and having a New Drug Application accepted in China for TP-03.
Nov 4, 2025, 9:30 PM
Tarsus Reports Strong Q3 2025 XDEMVY Sales and Provides Q4/Full-Year Guidance
TARS
Earnings
Guidance Update
New Projects/Investments
- Tarsus delivered $118.7 million in net product sales for XDEMVY in Q3 2025, with 103,000 bottles dispensed to patients.
- The company expects Q4 2025 net product sales for XDEMVY to be in the range of $140 million-$145 million, projecting full-year 2025 revenue of $440 million-$445 million.
- Tarsus plans to initiate a Phase 2 study for TP-04 (ocular rosacea) by year-end 2025, with top-line data anticipated in 2026, and expects to begin a Phase 2B study for TP-05 (Lyme disease prevention) in 2026.
- Full-year 2025 direct-to-consumer (DTC) investment is anticipated to be at the top end of the $70 million-$80 million range, and 2026 operating expenses are expected to be in line with 2025 SG&A spend.
Nov 4, 2025, 9:30 PM
Tarsus Pharmaceuticals Reports Strong Q3 2025 Financial Results and Pipeline Advancements
TARS
Earnings
Revenue Acceleration/Inflection
New Projects/Investments
- Tarsus Pharmaceuticals reported net product sales of $118.7 million for Q3 2025, marking a 147% increase year-over-year.
- The company's net loss for Q3 2025 improved to $12.6 million, compared to a net loss of $23.4 million in the same period of 2024.
- As of September 30, 2025, Tarsus held $401.8 million in cash, cash equivalents, and marketable securities.
- Tarsus plans to initiate a Phase 2 study of TP-04 for ocular rosacea in December 2025 and a Phase 2 study of TP-05 for Lyme disease prevention in 2026.
Nov 4, 2025, 9:08 PM
Tarsus Pharmaceuticals Reports Third Quarter 2025 Financial Results
TARS
Earnings
Revenue Acceleration/Inflection
New Projects/Investments
- XDEMVY net sales for the third quarter ended September 30, 2025, were approximately $119 million, marking a 147% year-over-year increase.
- The company reported a net loss of $12.6 million for Q3 2025, an improvement from a $23.4 million net loss in the same period of 2024.
- Weekly multi-patient prescribers for XDEMVY grew approximately 30% in Q3 2025 compared to Q2 2025, with more than 103,000 bottles delivered to patients.
- Tarsus plans to initiate a Phase 2 study for TP-04 (ocular rosacea) in December 2025 and for TP-05 (Lyme disease prevention) in 2026.
- As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $401.8 million.
Nov 4, 2025, 9:05 PM
Tarsus Pharmaceuticals Updates on XDEMVY Performance, Pipeline, and Market Strategy
TARS
Guidance Update
Product Launch
New Projects/Investments
- Tarsus Pharmaceuticals reported $102.7 million in net revenues for the last quarter and guided for 95,000 to 100,000 bottles distributed for Q3. Gross-to-net discounts are expected to improve to 43% to 45% for Q3 and reach the low 40% by year-end.
- XDEMVY has achieved over 90% insurance coverage and has been prescribed by over 20,000 eye doctors. The company is focusing on deepening prescribing patterns and increasing patient retreatment rates, which have recently exceeded 10% towards a 20% annualized target.
- The direct-to-consumer (DTC) campaign, with an expected spend of $70 million to $80 million in 2025, is driving demand and expanding the prescriber base.
- The pipeline includes TP-04 for ocular rosacea, with a Phase 2 trial starting later this year and data anticipated by the end of next year or early the following year. International expansion for XDEMVY is also underway, with potential European approval by 2027.
Sep 3, 2025, 2:28 PM
Tarsus Pharmaceuticals Reports Strong Xdemvy Sales for Q4 and Full Year 2024, Provides 2025 Outlook and Pipeline Updates
TARS
Earnings
Guidance Update
New Projects/Investments
- Tarsus Pharmaceuticals reported Xdemvy net product sales of $66.4 million for Q4 2024 and $180.1 million for the full year 2024, with 163,000 bottles dispensed in its first full calendar year.
- The company expanded its sales force to 150 representatives and achieved over 90% commercial and Medicare coverage for Xdemvy, with more than 15,000 target eye care physicians now prescribing.
- For Q1 2025, Tarsus expects to dispense 62,000 to 67,000 bottles of Xdemvy, anticipating strong annual growth for 2025 but with non-linear quarterly dynamics.
- Total operating expenses for FY 2024 were approximately $303.5 million, and the company ended 2024 with $291.4 million in cash and cash equivalents.
- Pipeline advancements include initiating a Phase 2 study for TP-04 in ocular rosacea in the second half of 2025 (expected cost $7-$10 million across 2025-2026) and a Phase 2 study for TP-05 in Lyme disease prevention in 2026.
Feb 25, 2025, 1:00 PM
Tarsus Pharmaceuticals Discusses XDEMVY Growth Strategy and 2025 Outlook
TARS
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- Tarsus Pharmaceuticals, a commercial-stage eye care company, reported over $113 million in net product sales for its FDA-approved product XDEMVY (for Demodex blepharitis) for the nine months ended Q3 2024.
- For 2025, the company's strategy focuses on driving "depth of adoption" for XDEMVY, supported by broad insurance coverage (including Medicare as of Q3 2024), continued evidence generation expanding the total addressable market, an increased sales force, and new consumer-directed (DTC) efforts.
- Tarsus anticipates muted growth in Q1 2025 for scripts dispensed, followed by a material ramp-up in Q2, and robust growth in Q4, with some expected seasonality in Q3.
- The gross-to-net discount is projected to increase by a couple of points in 2025 from Q4 2024 levels due to industry pressures, eventually stabilizing in the low 40% range.
- The company is also exploring new indications for ocular rosacea and has a pipeline product for Lyme disease prevention, while strategically considering preclinical/early-stage clinical asset acquisitions or on-market commercial assets in the anterior segment of eye care.
Feb 12, 2025, 3:00 PM
Tarsus Pharmaceuticals Discusses XDEMVY Performance and Pipeline Development
TARS
Revenue Acceleration/Inflection
New Projects/Investments
Guidance Update
- Tarsus Pharmaceuticals reported over $113 million in net product sales for XDEMVY for the nine months ended Q3 2024 and projects Q4 2024 revenue guidance of $50 million-$55 million.
- XDEMVY, the only FDA-approved therapy for Demodex blepharitis, has achieved over 80% patient population coverage, including Medicare, and has seen 13,000 out of 15,000 Eye Care Professionals (ECPs) write at least one script.
- Key growth drivers for XDEMVY include a 50% increase in sales representatives, a direct-to-consumer (DTC) campaign, and an expanded market opportunity (TAM) to 9 million patients following new data on Meibomian gland disease.
- The company is advancing its pipeline with a Phase II study for ocular rosacea, a condition affecting 15 million-18 million patients in the U.S., expected to start in the second half of 2025 with data readout in 2026. This new product is a customized ophthalmic gel using the same active ingredient as XDEMVY and will leverage the existing sales force.
- Tarsus anticipates muted growth in Q1 2025 for scripts, followed by a material ramp-up in Q2 2025, with a gross-to-net discount expected to increase by 1-2 points in Q4 2024 and further in 2025.
Feb 12, 2025, 3:00 PM
Quarterly earnings call transcripts for Tarsus Pharmaceuticals.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more